title: Utility of FDG PET/CT in the assessment of myeloid sarcoma.
abstract: OBJECTIVE
  Myeloid sarcoma (MS) is a rare extramedullary manifestation of acute myeloid leukemia that often presents during remission or disease relapse. With awareness of this clinical entity and the appropriate clinical history, MS can be detected despite its nonspecific radiologic features.
  
  
  CONCLUSIONS
  This article highlights the utility of (18)F-FDG PET/CT, which has high sensitivity in detecting early MS and provides a systemic overview of tumor burden, and its potential role in monitoring of treatment response.
authors.affiliation: Department of Diagnostic Radiology, Queen Mary Hospital, University of Hong Kong, Hong Kong. eyplee77@hku.hk
authors.forename: Elaine Yuen Phin
authors.initials: EY
authors.lastname: Lee
authors.forename: Marina-Portia
authors.initials: MP
authors.lastname: Anthony
authors.forename: Anskar Yu-Hung
authors.initials: AY
authors.lastname: Leung
authors.forename: Florence
authors.initials: F
authors.lastname: Loong
authors.forename: Pek-Lan
authors.initials: PL
authors.lastname: Khong
mesh_terms: D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D064847:Multimodal Imaging; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D023981:Sarcoma, Myeloid / Q000000981:diagnostic imaging* / Q000473:pathology; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18